Alpha-MSH

What is Alpha-MSH?

Alpha-melanocyte-stimulating hormone (α-MSH) is the endogenous 13-amino-acid peptide hormone (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) cleaved by prohormone convertases from pro-opiomelanocortin (POMC) — the same precursor that gives rise to ACTH, β-endorphin, and β- and γ-MSH. It is produced in the pituitary pars intermedia, in POMC neurons of the hypothalamic arcuate nucleus and nucleus tractus solitarius, and peripherally by keratinocytes, melanocytes, and immune cells. α-MSH is the natural agonist of the melanocortin receptor family: it binds MC1R on melanocytes to drive eumelanin synthesis and UV-protective pigmentation, MC3R and MC4R in the hypothalamus to regulate appetite and energy expenditure via the leptin-melanocortin satiety pathway, and MC5R in exocrine tissues. It is also a physiologically important anti-inflammatory and neuroimmunomodulatory peptide — a role retained by its C-terminal tripeptide KPV (α-MSH 11-13). α-MSH is not a 'research peptide' or supplement. It is a real hormone that every human produces. The molecules most commonly discussed on wellness and aesthetic sites — Melanotan I (afamelanotide), Melanotan II, setmelanotide, bremelanotide (PT-141), and the cosmetic antagonist Nonapeptide-1 — are all synthetic α-MSH analogs or antagonists engineered to amplify, restrict, or block the pharmacology of this endogenous hormone. Native α-MSH itself is not sold as a therapeutic or used as an exogenous drug in humans because it is too short-lived in circulation to be practical; the approved and investigational drugs in the melanocortin space are all protease-resistant analogs.

What Alpha-MSH Is Investigated For

Alpha-MSH is an endogenous hormone, not an injectable peptide sold to consumers. It is the parent molecule for essentially every melanocortin drug in the directory — Melanotan I (afamelanotide), Melanotan II, setmelanotide, bremelanotide (PT-141), and the C-terminal anti-inflammatory fragment KPV are all engineered analogs or fragments of α-MSH. The native 13-residue peptide has three well-validated physiological roles: pigmentation via MC1R on melanocytes (α-MSH released from keratinocytes after UV exposure is a core driver of tanning and eumelanin-based photoprotection), appetite and energy-balance control via MC4R in the hypothalamic paraventricular nucleus (the leptin → POMC → α-MSH → MC4R satiety pathway, loss of which causes severe monogenic obesity), and broad anti-inflammatory / neuroimmunomodulatory activity mediated in part by NF-κB suppression — a property largely retained by its C-terminal tripeptide KPV. The reason α-MSH itself is not an off-the-shelf therapeutic is pharmacokinetic: native α-MSH is rapidly degraded in circulation and has a half-life too short for practical dosing. Every approved melanocortin drug (Scenesse, Imcivree, Vyleesi) is a protease-resistant analog engineered specifically to overcome this limitation. Understanding α-MSH is the biological foundation for understanding the rest of the melanocortin cluster.

History & Discovery

The story of α-MSH spans more than a century. Early-20th-century physiologists observed that pituitary extracts darkened amphibian skin, and in 1916 Bennet Mills Allen and Philip E. Smith independently described a pituitary 'intermedin' factor responsible for the effect — the functional discovery of melanocyte-stimulating hormone activity. The first structural characterization came in the 1950s: Aaron Lerner's group at Yale and the University of Oregon teams working in parallel isolated α-MSH and β-MSH from pig and bovine pituitary pars intermedia extracts, and Klaus Hofmann's group at the University of Pittsburgh completed the total synthesis of α-MSH in the mid-1950s — one of the earlier peptide-hormone total syntheses and a practical demonstration that the 13-residue acetylated/amidated sequence was sufficient for biological activity. The relationship between α-MSH, ACTH, and β-endorphin was clarified in the 1970s and early 1980s with the identification of pro-opiomelanocortin (POMC) as the common precursor from which all three were cleaved by tissue-specific prohormone convertases. Donald Steiner's work on prohormone processing, combined with cDNA cloning of POMC by Shigetada Nakanishi and colleagues in 1979, established the molecular biology of the melanocortin family. Subsequent work mapped PC1/3 and PC2 as the primary convertases, with PC2 being specifically required for pituitary and brain α-MSH generation — a finding with clinical resonance in rare human PC1/3 deficiency syndromes producing obesity. The modern era of α-MSH pharmacology opened in 1992, when Roger Cone's group at the Vollum Institute (Oregon Health Sciences University) cloned the first melanocortin receptors MC1R and MC2R (Mountjoy et al., Science 1992; PMID 1325670), followed rapidly by MC3R, MC4R, and MC5R. This molecular characterization explained why a single hormone could control pigmentation, appetite, adrenal function, and exocrine secretion through tissue-specific receptor expression — and opened rational drug design against individual melanocortin receptors. The subsequent 30 years produced the drug cohort now on this site: Melanotan I and II from Mac Hadley and Victor Hruby's University of Arizona melanocortin program in the 1980s (developed as photoprotective analogs and, unexpectedly, a sexual-arousal lead that later became PT-141); afamelanotide (Scenesse) for erythropoietic protoporphyria, FDA-approved 2019; setmelanotide (Imcivree) for POMC/PCSK1/LEPR deficiency and later Bardet-Biedl syndrome and acquired hypothalamic obesity, FDA-approved starting in 2020; bremelanotide (Vyleesi) for female HSDD, 2019. In parallel, J. Michael Lipton and Anna Catania's group demonstrated in a series of papers starting in the late 1980s that α-MSH and its C-terminal tripeptide KPV (α-MSH 11-13) were potent endogenous anti-inflammatory agents — a role that the broader peptide-research community initially found surprising for a 'pigmentation hormone' but that has since been extensively replicated in ocular, CNS, gut, and skin inflammation models. This anti-inflammatory thread is the direct origin of the KPV drug program pursued for inflammatory bowel disease and skin inflammation. The ongoing modern story of α-MSH is primarily therapeutic — the mapping of which receptor subset to drug for which disease — and biomarker-based, with α-MSH levels occasionally measured in obesity, inflammatory, and dermatologic research contexts.

How It Works

α-MSH is the body's natural melanocortin hormone. It's cleaved from a larger precursor (POMC) and travels to different tissues where it tells cells to do different things depending on which melanocortin receptor is expressed: in skin melanocytes it drives tanning (MC1R), in the hypothalamus it signals 'you're full' after eating (MC4R, downstream of leptin), and in immune cells it dampens inflammation. Essentially every melanocortin drug on this site — Melanotan I, Melanotan II, setmelanotide, PT-141, KPV — is a synthetic tweak of α-MSH's structure.

Alpha-MSH (α-MSH) is generated by prohormone convertase PC1/3 and PC2-mediated cleavage of pro-opiomelanocortin (POMC), followed by C-terminal amidation (by peptidyl-glycine α-amidating monooxygenase, PAM) and N-terminal acetylation (opiomelanotropin-acetyltransferase), yielding the mature 13-residue acetylated/amidated hormone. POMC is expressed in the pituitary (corticotrophs and pars intermedia melanotrophs), the hypothalamic arcuate nucleus, the nucleus tractus solitarius of the brainstem, and peripherally in keratinocytes, melanocytes, and immune cells. α-MSH is degraded by peptidases including prolylcarboxypeptidase (PRCP), giving a plasma half-life too short for practical exogenous dosing as a drug. α-MSH is the endogenous agonist of the melanocortin receptor family — MC1R through MC5R, all Gs-coupled GPCRs that signal through adenylate cyclase, cAMP elevation, and downstream PKA/CREB activation. At MC1R on epidermal melanocytes, α-MSH binding drives CREB phosphorylation and upregulation of MITF, the master melanogenic transcription factor, which in turn drives expression of tyrosinase, TRP-1, and TRP-2 and shifts melanin synthesis toward eumelanin over pheomelanin. α-MSH released from keratinocytes after UV exposure is a primary driver of the tanning response, and MC1R signaling also enhances nucleotide excision repair of UV-induced DNA photoproducts and modulates antioxidant defenses. At MC4R in the hypothalamic paraventricular nucleus (and to a lesser extent MC3R), α-MSH released from arcuate-nucleus POMC neurons is a core anorexigenic signal. Leptin binds LepRb on POMC neurons, stimulating POMC transcription and α-MSH release, which activates MC4R on downstream neurons to suppress appetite and increase sympathetic tone and energy expenditure. AgRP (agouti-related peptide) from a parallel arcuate-nucleus neuronal population is the endogenous MC3R/MC4R antagonist/inverse agonist and opposes the α-MSH satiety signal. Disruption of this pathway — loss-of-function mutations in POMC, PCSK1 (cleavage enzyme), LEPR (upstream), or MC4R — produces the well-characterized monogenic obesity syndromes that setmelanotide is approved to treat. Acquired hypothalamic injury (craniopharyngioma surgery, radiation, trauma) disrupts the same circuit downstream of POMC neurons. α-MSH's anti-inflammatory and neuroimmunomodulatory activity operates through at least two routes: direct MC1R, MC3R, and MC5R signaling on immune cells (macrophages, neutrophils, monocytes) to suppress pro-inflammatory cytokine production, and a fragment-mediated route through the C-terminal tripeptide KPV (α-MSH 11-13), which translocates intracellularly and directly inhibits NF-κB p65 nuclear translocation independent of melanocortin-receptor activation. NF-κB inhibition downstream of both routes reduces TNF-α, IL-1β, IL-6, and IL-8 production. This is the pharmacological basis for the KPV drug program and for the broader anti-inflammatory framing of α-MSH in dermatology, IBD, ocular immunology, and CNS inflammation contexts. MC5R, expressed in exocrine tissues, mediates effects on sebaceous and lacrimal secretion. MC2R is the ACTH receptor and is not significantly activated by α-MSH — a pharmacological distinction that is the basis for why α-MSH signaling does not produce adrenal cortisol release despite overlapping POMC origin.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Alpha-MSH:

• 01Tissue-specific POMC processing — the ratios of α-MSH, β-MSH, γ-MSH, ACTH, β-endorphin, and N-POMC produced across pituitary pars distalis vs. pars intermedia vs. hypothalamic arcuate nucleus vs. keratinocytes are incompletely mapped, and how these ratios shift in disease states is an active research area.
• 02Contribution of peripheral vs. central α-MSH to systemic physiology — whether keratinocyte- and immune-cell-derived α-MSH has meaningful endocrine effects beyond local autocrine/paracrine signaling is unresolved.
• 03α-MSH in human melanoma — evidence is split between α-MSH preventing melanoma (via enhanced DNA repair and eumelanin-based photoprotection) and α-MSH signaling being overexpressed in established metastatic melanoma as a potential driver of immune escape and therapy resistance. The clinical implications of MC1R pharmacology in melanoma risk and treatment are not settled.
• 04Role in human ocular immunoprivilege — α-MSH is a central mediator of anterior chamber immune deviation in animal models, but translation to human ocular disease therapeutics is preliminary.
• 05Biomarker utility — circulating α-MSH measurement is technically feasible but clinical interpretation and reference ranges are not standardized, and the marker is not widely used in endocrinology practice.
• 06Endogenous α-MSH changes in obesity, inflammatory disease, and neurodegeneration — exploratory data suggest hypothalamic melanocortin tone is altered in several chronic diseases, but whether measuring or modulating α-MSH itself (rather than downstream receptors) has clinical utility is open.
• 07Why native α-MSH has not been successfully formulated for human therapeutic use — depot formulations, fusion proteins, or peptidase-resistant modifications other than the classical Nle4/D-Phe7 substitutions have not been advanced clinically, and whether a near-native α-MSH product could be a useful therapy remains an unanswered drug-development question.

Forms & Administration

α-MSH as the native 13-residue peptide is not a human therapeutic product. It is supplied by biochemical vendors as a research reagent (lyophilized powder, typically 1 mg vials) for cell-culture and preclinical animal work. Its plasma half-life is too short for practical human dosing. Clinically relevant melanocortin-pathway pharmacology in humans is achieved via engineered analogs: Scenesse (afamelanotide, 16 mg biodegradable subcutaneous implant, every 60 days, for EPP); Imcivree (setmelanotide, daily subcutaneous injection, for rare monogenic obesity, Bardet-Biedl syndrome, and acquired hypothalamic obesity); Vyleesi (bremelanotide, 1.75 mg subcutaneous injection on demand, for premenopausal HSDD); and research-chemical Melanotan I and II (not approved, with regulatory warnings). None of these is native α-MSH — they are rationally designed protease-resistant and/or receptor-selective derivatives.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions